HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF‐ β and TNFSF13B/VEGF‐A Axis
Advanced Science · 2023
DOI: 10.1002/advs.202206955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Lei Yin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Putuo People's Hospital, Tongji University, Shanghai, 200060, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Ruijin Hospital Youth Incubation, Sailing Program of Shanghai Science and Technology Commission.
Abstract (Originalsprache)
Accumulating evidence shows HOOK1 disordered in human malignancies. However, the clinicopathological and biological significance of HOOK1 in renal cell carcinoma (RCC) remains rarely studied. In this study, the authors demonstrate that HOOK1 is downregulated in RCC samples with predicted poorer clinical prognosis. Mechanistically, HOOK1 inhibits tumor growth and metastasis via canonical TGF‐ β /ALK5/p‐Smad3 and non‐canonical TGF‐ β /MEK/ERK/c‐Myc pathway. At the same time, HOOK1 inhibits RCC angiogenesis and sunitinib resistance by promoting degradation of TNFSF13B through the ubiquitin‐proteasome pathway. In addition, HOOK1 is transcriptionally regulated by nuclear factor E2F3 in VHL dependent manner. Notably, an agonist of HOOK1, meletin, is screened and it shows antitumor activity more effectively when combined with sunitinib or nivolumab than it is used alone. The findings reveal a pivotal role of HOOK1 in anti‐cancer treatment, and identify a novel therapeutic strategy for renal cell carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Putuo People's Hospital, Tongji University, Shanghai, 200060, P. R. China.
- Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China.
- Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China.
- Department of General Surgery, Hepatobiliary Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P. R. China.
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, P. R. China.
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, 230032, P. R. China.
ORCID-Profile: Lei Yin
Förderung
- National Natural Science Foundation of China
- Ruijin Hospital Youth Incubation
- Sailing Program of Shanghai Science and Technology Commission
- National Ministry of Education
- National Science Foundation of Hubei province
- Tongji Hospital Returnees Initiation Fund
Zitieren
APA
Yin, L., Li, W., Chen, X., Wang, R., Zhang, T., Meng, J., Li, Z., Xu, L., Yin, R., Cheng, B., & Yang, H. (2023). HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF‐ β and TNFSF13B/VEGF‐A Axis. Advanced Science. https://doi.org/10.1002/advs.202206955
Vancouver
Yin L, Li W, Chen X, Wang R, Zhang T, Meng J, et al. HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF‐ β and TNFSF13B/VEGF‐A Axis. Advanced Science. 2023. doi:10.1002/advs.202206955
BibTeX
@article{Yin2023,
author = {Yin, Lei and Li, Wenjia and Chen, Xuxiao and Wang, Ronghao and Zhang, Tao and Meng, Jialin and Li, Zhao and Xu, Li and Yin, Rui and Cheng, Bo and Yang, Huan},
title = {HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF‐ β and TNFSF13B/VEGF‐A Axis},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202206955}
}
EUVIMED